Investigating the role of HMGB1 in skin cancer for patients with a rare genetic disease.
HMGB1 in EB-Associated Squamous Cell Carcinoma
This study is looking at how a protein called HMGB1 affects skin cancer development in people with a rare skin condition called recessive dystrophic epidermolysis bullosa (RDEB), and it aims to find out if blocking this protein can help prevent tumors from forming.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10868435 on NIH RePORTER |
What this research studies
This research focuses on recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic condition that leads to severe skin wounds and a high risk of early-onset squamous cell carcinoma (SCC). The study aims to understand how a protein called HMGB1 contributes to cancer development in RDEB patients by examining its effects on inflammation and genomic stability in skin cells. Researchers will use both laboratory techniques and a mouse model to test whether blocking HMGB1 can prevent tumor formation. This could lead to new therapeutic strategies for managing skin cancer in these patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with recessive dystrophic epidermolysis bullosa who are at risk for squamous cell carcinoma.
Not a fit: Patients without recessive dystrophic epidermolysis bullosa or those who do not have a history of skin cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that reduce the risk of skin cancer in patients with RDEB.
How similar studies have performed: While the role of HMGB1 in other cancers has been studied, this specific investigation in RDEB is novel and has not been extensively tested.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Bui, Kacey Linnea Guenther — University of Minnesota
- Study coordinator: Bui, Kacey Linnea Guenther
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.